Brainstorm Cell Therapeutics (BCLI) Reports First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
Tweet Send to a Friend
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced today Cleveland Clinic as the first U.S. clinical site contracted for a planned ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
